Correlation of Serum Calprotectin Expression with Clinical Response in Juvenile Idiopathic Arthritis Patients Treated with a Tumor Necrosis Factor Inhibitor
10.12007/j.issn.0258-4646.2017.09.013
- VernacularTitle:钙卫蛋白在肿瘤坏死因子抑制剂治疗幼年特发性关节炎临床应答中的预测作用
- Author:
Hui LI
1
;
Wei CAI
;
Kailan CHEN
Author Information
1. 武汉市妇女儿童医疗保健中心血液肿瘤科
- Keywords:
juvenile idiopathic arthritis;
calprotectin;
tumor necrosis factor inhibitor;
clinical response
- From:
Journal of China Medical University
2017;46(9):825-829
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation of serum calprotectin (MRP8/14) expression with clinical response in Chinese juvenile idiopathic arthritis (JIA) patients treated with a tumor necrosis factor (TNF) inhibitor.Methods Seventy-two JIA patients and 30 health volunteers (HCs) were enrolled in this prospective study.All JIA patients received etanercept for 24 weeks.Serum was collected from JIA patients at baseline before treatment and from HCs.Clinical response was defined according to the American College of Rheumatology (ACR) Pedi 50 criteria.Results Serum MRP8/14 expression was greater in JIA patients than in HCs (P ＜ 0.001).Serum MRP8/14 level was greater in responders than in non-responders (area under the receiver operating characteristic curve,0.823;95％ CI:0.706-0.939).Univariate and multivariate logistic analysis showed that high serum MRP8/14 expression was an independent predictive factor for clinical response (P =0.003).Conclusion Serum MRP8/14 level can be used as a convincing and novel biomarker for clinical response in JIA patients treated with a TNF inhibitor.
